Clinical Trial Update: Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing NALIRIFOX to a modified Gemcitabine, Nab-Paclitaxel, and Cisplatin regimen for locally advanced or metastatic pancreatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Leucovorin (folinic acid)
• Liposomal irinotecan (liposomal irinotecan)
• NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Status: RECRUITING